Annex 11 2011 Version vs. Annex 11 2025 Draft Version: What are the Differences and Enhancements?

December 15, 2025

The GMP/GDP Inspectors Working Group and the PIC/S Committee jointly recommended that the current version of Annex 11 on Computerised Systems be revised to reflect changes in regulatory and manufacturing environments. The revised guideline should clarify requirements and expectations from regulatory authorities, and remove ambiguity and inconsistencies

Annex 11 Background

In 2011, EudraLex The Rules Governing Medicinal Products in the European Union published Annex 11: Computerised Systems as part of Volume 4, Good Manufacturing Practice, Medicinal Products for Human and Veterinary. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components that together fulfill certain functionalities.

Annex 11 Computerised Systems 2025 Draft Version

The GMP/GDP Inspectors Working Group and the PIC/S Committee jointly recommended that the current version of Annex 11 on Computerised Systems, be revised to reflect changes in regulatory and manufacturing environments. The revised guideline would clarify requirements and expectations from regulatory authorities and remove ambiguity and inconsistencies.

The updated Annex 11 outlines the requirements for the use of computerised systems in GMP-regulated activities, thereby ensuring product quality, patient safety, and data integrity.

Let's understand the differences and what the new 2025 draft version of Annex 11 emphasizes

Key Differences & Enhancements in Annex 11 2025 Draft

Expanded Scope

  • More detailed, lifecycle-wide.
  • Includes more details on vendor management, audit trails, SLAs, backups, security incidents, and regulatory shifts.
  • End-to-end lifecycle approach: URS → design → testing → operation → retirement.
  • Explicit requirement for URS traceability and traceability matrix.

Change Impact Assessment

  • Mandates consideration of combined change effects and configuration auditing for detecting unauthorized changes.

Data Integrity Focus

  • Central focus.
  • Strong emphasis on reviewing data integrity assessment outcomes.
  • Explicit (ALCOA+, metadata)

Final review at decommissioning

  • Explicitly required.
  • Requires a final review when retiring a system.

Identity, Access Management, and Security

  • More details and clarity on access controls.
  • Major section, including MFA.

Risk-Based Frequency

  • Formalizes frequency planning and justification based on product quality, patient safety, and data integrity risk.

Cloud/SaaS

  • Now explicitly covered.

Periodic Review

  • Strong requirements added.

Suppliers

  • Heavily emphasized (cloud, GxP)
  • Expanded: ensure supplier quality systems and assess supplier risk during validation.

Audit Trail

  • Mandatory audit trails for systems that control processes or manage data.

Data Handling

  • Explicit Data Handling section

Testing Rigor

  • Documentation of test scenarios, data limits, error handling, and automated tool assessment.

Data Handling in Annex 11 2011 vs 2025 Draft

Area

Version 2011

Version 2025 Draft

Manual Data Entry (Input Verification)

Not specifically addressed. 

Requires plausibility checks for manually entered critical data; alerts for out-of-range values.

Data Transfer Between Systems

General reference to accuracy. 

Encourages validated electronic interfaces over manual transcription; manual transcription must be controlled.

Data Migration

Briefly mentioned under validation.

Full clause on migration as a validated process considering both sending/receiving systems. Requirement to validate value/meaning retention during migration.

Encryption

Not mentioned.

Critical data should be encrypted where applicable.

Critical Data

Implied, not detailed.

Emphasizes “critical data” consistently across subsections.

Access Control & Management in Annex 11 2011 vs 2025 Draft

Area

Version 2011 Section 12: Security

Version 2025 Draft Section 11: Identity and Access Management

User Accounts 

No mention of shared vs. individual accounts. 

Unique, personal accounts only. Shared accounts allowed only for read-only access. Shared write access is a data integrity violation.

Account Lifecycle 

Creation, change, and cancellation should be recorded.

Continuous access management required: accounts should be granted, modified, and revoked promptly as roles change. 

Authentication Requirements

General mention of personal codes with passwords. 

Specific authentication criteria: usernames and passwords, or methods of equal or higher assurance. Token-only logins not acceptable. 

Password Security 

Implied via general system controls. 

Explicit password rules: secure, confidential, unique, long, complex, changed on first login, not based on dictionary or personal data. 

Multifactor Authentication (MFA) 

Not mentioned. 

MFA for remote access to critical systems. 

Account Lockout

Not mentioned.

Auto-lockout after failed logins; unlock only after risk is removed.

Session Timeout / Logout 

Not mentioned.

Inactivity logout enforced by the system. Users cannot disable it. 

Access Logging 

User actions must be logged with identity and timestamp.

Access logs must capture login/logout times, user roles, inactivity logouts; must be sortable/searchable or exportable.

Segregation of Duties 

Not mentioned. 

Users must have minimum necessary access for their role. 

Least Privilege Principle 

Not mentioned. 

Users must have minimum necessary access for their role. 

Periodic Access Reviews

Not mentioned. 

Recurrent access reviews required by managers. Applies to users and roles. Frequency should match risk. 

Audit Trails in Annex 11 2011 vs 2025 Draft

Area

Version 2011 Section 9: Audit Trails

Version 2025 Draft Section 12: Audit Trails

General Requirement 

Consideration should be given to having audit trails based on risk. 

Mandatory audit trails for systems that control processes or manage data. 

Reason for Change 

Should be documented. 

System must prompt and capture a reason for any data change. 

Audit Trail Integrity 

Should be available, readable, and regularly reviewed. 

Should be enabled and locked at all times. Any attempt to edit or disable it must itself be logged. 

Access and Review 

Available in intelligible form and reviewed regularly. 

Should be sortable/searchable or exportable. Tools for review are encouraged. 

Audit Trail Review 

General requirement for regular review. 

Requires documented SOPs defining who, what, when, and how reviews are conducted. Reviews should be risk-based and timely. 

Reviewer

Not specified. 

Must be done by independent personnel. 

Periodic Reviews in Annex 11 2011 vs 2025 Draft

Area

Version 2011 Section 11: Periodic Evaluation

Version 2025 Draft Section 14: Periodic Reviews

Terminology 

Periodic evaluation 

Periodic review 

Purpose 

Confirm system remains validated and GMP compliant. 

Confirm system is still fit for intended use, validated, and identify if revalidation is needed. Assess impact on product quality, patient safety, and data integrity. 

Scope

Review of deviations, changes, incidents, problems, validation status, and performance. 

  • System changes (hardware, software, configuration, infrastructure, interfaces)
  • Document changes
  • Combined change impact
  • Audit trail & access reviews
  • CAPAs, deviations, incidents, problems, security threats
  • Maintenance, calibration, SLAs, KPIs
  • Backup, recovery, archival adequacy
  • Data integrity assessments
  • Regulatory changes

Follow-up Items

General references to change/deviation records.

Explicit tracking of previous review actions, audits, inspections, and risk assessments. 

Frequency

Not clearly defined.

Should be planned, justified, and risk-based. Includes a final review at system retirement. 

Need more help with Annex 11 compliance and CSV activities?

Don’t have the time or expertise? Let our experienced consultants implement compliance for you. Contact us today.

TAGS:

Sophisticated pharmaceutical manufacturing machines in progress.

April 24, 2023

Revised Annex 1, EudraLex Volume 4: Deadline to Comply: August 2023

The deadline to comply with the revised EudraLex Volume 4, Annex 1 is August 25th, 2013. Only for a sole point (point 8.123: "product transfer/loading/unloading areas for lyophilizers“) a later...

October 8, 2020

EudraLex Volume 4, Annex 1 Update: What You Need to Know

EudraLex Volume 4, Annex 1 provides guidance for the manufacturing of sterile medicinal products that are intended for the European market. It has been updated several times, with the latest revision...

Annex 21: What You Need to Know

It’s finally here, a guidance on how to handle medicinal products imported from outside EU/EEA. If you’ve ever wondered what the expectations are on these imported medicinal products, you’re in for a...